The Fund

On September 3, 2006, 22 year-old Ted Mullin died from sarcoma, a rare form of cancer of connective tissues. Upon his death, Ted's parents, Mary Henry and Rick Mullin, established the Ted Mullin Fund for Pediatric Sarcoma Research at The University of Chicago Medicine Comer Children's Hospital where Ted received treatment.

Since 2006, Mullin family and friends have raised almost $800,000 for the Ted Mullin Fund, allowing The University of Chicago Medicine (UCM) to launch its pediatric sarcoma research program. Money raised acts as seed funding for Comer Children's Hospital's pediatric sarcoma research program. The Ted Mullin Fund has supported research into novel chemotherapy/biology agents for sarcomas, new ways to administer chemotherapy in this disease, techniques to visualize more accurately the tumor response in the patient, novel genomics strategies to identify high-risk sarcoma patients, molecular techniques to personalize therapy to maximize benefit while reducing treatment-related toxicity, and treatments for metastatic or resistant disease that use the patient's own immune system to attack residual tumors. Each summer, UCM hosts Ted Mullin Fund Scholars in pediatric cancer laboratories, giving collegiate Ted Mullin "Hour of Power" participants an opportunity to advance their interest in science and cancer biology. UCM is celebrating the first anniversary of the Adolescent and Young Adult Oncology Program that initially focused on leukemia and sarcoma, and now has added lymphoma to the program. Future plans include, in collaboration with other national programs, the establishment of a consortium to facilitate more rapid development and availability of new molecular and biologic therapeutics.

Philanthropy, in the form of private donations for basic science research to funds like the Ted Mullin Fund, is essential in ultimately finding a cure for sarcoma. Unlike research in other more common types of cancer, where large-scale clinical trials involving thousands of patients have enabled investigators to gain insights into risk factors and effective treatments, breakthroughs for sarcoma patients will come from basic and translational research, like the kind taking place at the University of Chicago.

The Ted Mullin Fund's major fundraiser is the Ted Mullin "Leave it in the Pool" Hour of Power Relay for Sarcoma Research.

The Ted Mullin Fund maintains a Collective Giving Fund with FJC. FJC is an IRS-recognized 501(c)(3) organization and as such, all donations made to the Ted Mullin Fund are tax-deductible to the extent allowed by law.